In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by...
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on a new form of cancer...
Inven2’s core business is innovation. We contribute in the process of commersialising good ideas from talented researchers, turning them into products and services that make a difference.
Inven2 work closely with hospitals and companies to make sure clinical studies are completed quick and efficient, to the best for Norwegian patients.
Key figures 2010 – 2020
# Ideas evaulated (DOFI)
# Companies established
# Licence agreements
# New patent applications
MNOK transferred back to research, innovation and inventors
# Clinical Trials managed